Starting testosterone treatment is associated with an increased risk of venous thromboembolism (VTE), peaking within 6 months and declining thereafter.
Men treated with implantable testosterone pellets have a statistically significant increase in mean hematocrit, but it is unlikely to be clinically relevant.
Once-daily testosterone solution 2% (T-sol) is safe and improves sex drive and energy in men with androgen deficiency.
Once-daily 2% testosterone solution (T-sol) is safe and effective for sex drive and energy in hypogonadal men.
Men using testosterone gel experienced improvements in sex drive, sexual activity, and erectile function.
Results showed a decreased prevalence of anemia and components of metabolic syndrome after 54 weeks of treatment.
Both low testosterone and sarcopenia tied to increased mortality, with low testosterone being a better predictor.
Daily topical testosterone restored normal testosterone levels in hypogonadal men
Sexual function and mood and depressive symptoms were improved in older men who received testosterone therapy.
Selective estrogen receptor modulators may offer a viable treatment option for men with secondary hypogonadism.